On July 23, 2014, the U.S. Food and Drug Administration approved Zydelig (idelalisib) to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies. More >
Welcome to Focus on FL
The FocusOnFL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by follicular lymphoma (FL).
We invite you to browse the website to learn more about follicular lymphoma and the resources offered by the Lymphoma Research Foundation.
Getting the Facts
Follicular Lymphoma is typically a slow-growing, or indolent, form of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes, making it a B-cell lymphoma. This cancer, which accounts for roughly 20 percent to 30 percent of all NHL cases, usually takes several years to develop.
Recent research into follicular lymphoma has led to significant advancements in the understanding of the disease. Research continues on multiple fronts to develop better treatments for patients. We hope you will find the information presented here useful in understanding your disease and discussing it with your healthcare team.